Floatz logo

Irinotecan

Microsatellite Stable

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Microsatellite Stable cohort.

Asset / SponsorPhaseRating
Eloxatin
M.D. Anderson Cancer Center
Phase 2BB
Epirubicin
NextCure, Inc.
Phase 2B
Pembrolizumab
NextCure, Inc.
Phase 2B
Cyclophosphamide
NextCure, Inc.
Phase 2B
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2B

View all 18 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →